EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists

Alla A Boshchenko iD, Leonid N Maslov iD, Alexander V Mukhomedzyanov iD, Olga A Zhuravleva, Alisa S Slidnevskaya, Natalia V Naryzhnaya iD, Arina S Zinovieva, Philipp A Ilinykh

International Journal of Molecular Sciences · 30.04.2024 · 25 (9) · 4900

DOI: 10.3390/ijms25094900 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.04.2024. Verfasst von Alla A Boshchenko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Atherosclerosis and Chronic Coronary Heart Disease, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Acad…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor, Cardiotonic Agents, Signal Transduction, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, Minestry of Science and Education of Russion Federation state assignment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The high mortality rate among patients with acute myocardial infarction (AMI) is one of the main problems of modern cardiology. It is quite obvious that there is an urgent need to create more effective drugs for the treatment of AMI than those currently used in the clinic. Such drugs could be enzyme-resistant peptide analogs of glucagon-like peptide-1 (GLP-1). GLP-1 receptor (GLP1R) agonists can prevent ischemia/reperfusion (I/R) cardiac injury. In addition, chronic administration of GLP1R agonists can alleviate the development of adverse cardiac remodeling in myocardial infarction, hypertension, and diabetes mellitus. GLP1R agonists can protect the heart against oxidative stress and reduce proinflammatory cytokine (IL-1β, TNF-α, IL-6, and MCP-1) expression in the myocardium. GLP1R stimulation inhibits apoptosis, necroptosis, pyroptosis, and ferroptosis of cardiomyocytes. The activation of the GLP1R augments autophagy and mitophagy in the myocardium. GLP1R agonists downregulate reactive species generation through the activation of Epac and the GLP1R/PI3K/Akt/survivin pathway. The GLP1R, kinases (PKCε, PKA, Akt, AMPK, PI3K, ERK1/2, mTOR, GSK-3β, PKG, MEK1/2, and MKK3), enzymes (HO-1 and eNOS), transcription factors (STAT3, CREB, Nrf2, and FoxO3), KATP channel opening, and MPT pore closing are involved in the cardioprotective effect of GLP1R agonists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 ReceptorCardiotonic AgentsSignal TransductionGlucagon-Like Peptide-1 Receptor AgonistsHumansAnimalsPeptidesMyocardial Reperfusion InjuryMyocardial InfarctionMyocytes, Cardiac

Stichwörter der Autor:innen

adverse remodeling of the heartdiabetic cardiomyopathyglucagon-like peptide-1hearthypertensionischemia/reperfusionkinasesregulated cell death

Substanzen

Glucagon-Like Peptide-1 ReceptorCardiotonic AgentsPeptidesGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Atherosclerosis and Chronic Coronary Heart Disease, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634012 Tomsk, Russia.
  • Laboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634012 Tomsk, Russia.
  • Department of Pathology, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.

ORCID-Profile: Alla A Boshchenko, Leonid N Maslov, Alexander V Mukhomedzyanov, Natalia V Naryzhnaya

Förderung

  • Russian Science Foundation
  • Minestry of Science and Education of Russion Federation state assignment

Zitieren

APA

Boshchenko, A. A., Maslov, L. N., Mukhomedzyanov, A. V., Zhuravleva, O. A., Slidnevskaya, A. S., Naryzhnaya, N. V., Zinovieva, A. S., & Ilinykh, P. A. (2024). Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists. International Journal of Molecular Sciences, 25(9), 4900. https://doi.org/10.3390/ijms25094900

Vancouver

Boshchenko AA, Maslov LN, Mukhomedzyanov AV, Zhuravleva OA, Slidnevskaya AS, Naryzhnaya NV, et al. Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists. International Journal of Molecular Sciences. 2024;25(9):4900. doi:10.3390/ijms25094900

BibTeX
@article{Boshchenko2024,
  author = {Boshchenko, Alla A and Maslov, Leonid N and Mukhomedzyanov, Alexander V and Zhuravleva, Olga A and Slidnevskaya, Alisa S and Naryzhnaya, Natalia V and Zinovieva, Arina S and Ilinykh, Philipp A},
  title = {Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {9},
  pages = {4900},
  doi = {10.3390/ijms25094900}
}
Kostenlos starten →